Hi all, have just stumbled across IMU and am trawling through...

Hi all, have just stumbled across IMU and am trawling through the many threads, looks great on the surface however one thing i cant seem to soften and hoping people can help with is the clinical risk, is it all just early days pipeline stuff?

Looks like HER-Vaxx phase 3 won't be able to start until optimistically Q3 2022 and would probably need to run for 24 months. So perhaps Q4 2024 for Phase 3 readouts and then another 12 months for approval application.

According to their latest presentation, the Phase 2 trial for CF33 won't start until Q2 2022 and will need to run for 24 months. So that means early 2025 at the earliest to start a Phase 3 trial that will be needed for approval ( assume another 24 - 36 months before an approval application can be submitted, nominally 2027 at the earliest ).

I guess IMU is aiming for a buyout occurring on the back of Phase 1 & 2 trials but the clinical risk for IMU to get to this point very high.